NCT06387381招募中早期 1 期
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
First Affiliated Hospital of Chongqing Medical University1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年5月20日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Diagnostic efficacy
研究概览
简要总结
As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •At least 18 years of age.
- •Signed informed consent.
- •Patients with suspected or newly diagnosed or previously malignant disease, with either PSMA or FAP positive expression (supporting evidence may include MRI, CT, and pathology report, etc).
排除标准
- •Patients with non-malignant disease.
- •Patients with pregnancy.
- •The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
- •Known or expected hypersensitivity to 68Ga-PSFA or any of its components.
- •Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
研究组 & 干预措施
68Ga-PSFA
Experimental
Patients will receive a single administration of 68Ga-PSFA.
干预措施: 68Ga-PSFA (Drug)
结局指标
主要结局
Diagnostic efficacy
时间窗: 15 days
The sensitivity, specificity, and accuracy of 68Ga-PSFA PET
次要结局
未报告次要终点
研究者
Xiaoyang Zhang
Principal Investigator
First Affiliated Hospital of Chongqing Medical University
研究点 (1)
Loading locations...
相似试验
招募中
不适用
68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDGSSTR2Positron-Emission TomographyFAPNCT05873777The First Affiliated Hospital of Xiamen University30
招募中
不适用
68Gallium-Prostate Specific Membrane Antigen (68Ga-PSMA) Positron Emission Tomography (PET) as a potential Imaging biomarker post tyrosine kinase inhibition of metastatic clear cell Renal cell Carcinoma (PIRC) – a pilot studyclear cell renal cell carcinomaACTRN12621000651886Olivia Newton-John Cancer Research Institute20
招募中
不适用
68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer PatientsProstate CancerNCT05324332Peking Union Medical College Hospital50
已完成
不适用
68Ga-PSMA PET/CT Imaging in Assessment of Prostate CancerPET/CTProstate Specific Membrane AntigenIMAGENCT05134064RenJi Hospital66
招募中
早期 1 期
68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic CancerPancreatic CancerNCT05875753Peking Union Medical College Hospital50